Henry Schein (HSIC) Resumen de Acciones
Henry Schein, Inc. ofrece productos y servicios sanitarios a odontólogos y médicos de todo el mundo. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 1/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
HSIC Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Henry Schein, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$74.21 |
| Máximo en las últimas 52 semanas | US$89.29 |
| Mínimo de 52 semanas | US$61.95 |
| Beta | 0.82 |
| Cambio en 1 mes | -4.99% |
| Variación en 3 meses | -6.74% |
| Cambio de 1 año | 3.57% |
| Variación en 3 años | -0.95% |
| Variación en 5 años | -2.41% |
| Variación desde la OPV | 1,204.79% |
Noticias y actualizaciones recientes
Recent updates
Artículo de análisis • May 08
Henry Schein, Inc. Just Recorded A 8.1% EPS Beat: Here's What Analysts Are Forecasting Next
Henry Schein, Inc. ( NASDAQ:HSIC ) shareholders are probably feeling a little disappointed, since its shares fell 5.5...
Actualización de narrativa • Apr 26
HSIC: Improving Dental Demand And Buybacks Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein reflects a modest upward adjustment in fair value to about $90 per share, as analysts incorporate refreshed models following recent Q4 results, new initiations, and several target raises across the Street. Analyst Commentary Recent research updates on Henry Schein show a mixed but generally constructive tone, with several firms revising models after Q4 results and initial FY26 guidance.Actualización de narrativa • Apr 11
HSIC: Rising Dental Demand And New CEO Transition Are Expected To Support Upside
Henry Schein's updated analyst price target edges slightly lower to about $89, as analysts refine their models following recent Q4 results and revised long-term growth assumptions across the Street. Analyst Commentary Street research around Henry Schein has turned more constructive overall, with several firms updating models following the Q4 print and initial FY26 guidance.Actualización de narrativa • Mar 28
HSIC: Rising Dental Demand And New CEO Are Expected To Support Upside
Narrative Update on Henry Schein The updated analyst price target for Henry Schein edges up to $90.00, reflecting a series of target increases across the Street as analysts factor in better than expected Q4 results, initial FY26 guidance, refreshed models, and improved visibility on growth and end market demand. Analyst Commentary Street research on Henry Schein clusters around higher price targets following Q4 results and initial FY26 guidance, with most firms updating their models and a mix of Outperform, Overweight, Neutral, Hold, and Market Perform ratings.Actualización de narrativa • Mar 13
HSIC: Improving Dental Demand And New CEO Leadership Will Support Upside
The analyst price target for Henry Schein has been raised from $83.21 to $89.79, reflecting updated models that factor in Q4 results, initial FY26 guidance, and what analysts describe as better growth visibility and a more supportive demand backdrop. Analyst Commentary Across the Street, recent research points to a more constructive stance on Henry Schein following Q4 results and initial FY26 guidance, with several firms revising their models and resetting price targets.
Nueva narrativa • Feb 25
Cloud Software And Specialty Products Will Reshape This Healthcare Distributor’s Future Earnings Power
Catalysts About Henry Schein Henry Schein is a global distributor of dental and medical products and services with growing software, specialty and value-added solutions for healthcare providers. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Feb 25
HSIC: Steadier Dental Demand And CEO Transition Will Support Balanced Outlook
Analysts have nudged their fair value estimate for Henry Schein up from $78.14 to $83.21, citing higher Street price targets and commentary about steadier organic growth and improving dental demand as the main supports for the updated view. Analyst Commentary Recent Street research on Henry Schein leans constructive, with several firms lifting price targets and, in one case, upgrading the rating as sentiment around dental demand and organic growth improves.Actualización de narrativa • Feb 10
HSIC: Revised Assumptions And CEO Transition Will Support Balanced Earnings Outlook
Analysts have increased their price target on Henry Schein by US$7, citing updated assumptions around revenue growth, margins, and future P/E levels that contribute to a revised valuation view. Analyst Commentary Recent research behind the US$7 upward move in the price target focuses on refreshed assumptions for Henry Schein’s revenue trajectory, margin profile, and future P/E levels.Actualización de narrativa • Jan 25
HSIC: Q3 Beat And CEO Transition Will Support Range-Bound Earnings Momentum
Narrative Update: Henry Schein The analyst price target for Henry Schein has moved slightly higher by about US$0.50, as analysts point to recent price target increases and a "clean beat" in Q3 that they see as supporting a modestly higher fair value while still viewing the shares as range bound. Analyst Commentary Recent Street commentary on Henry Schein points to a mixed setup, with some bullish analysts nudging price targets higher on the back of Q3 execution and others still reluctant to see a clear path out of the stock's trading range.Actualización de narrativa • Jan 11
HSIC: Q3 Beat And AI Partnerships Will Support Range-Bound Earnings Momentum
Analysts have raised their price target on Henry Schein to US$75 from US$71, citing a clean Q3 earnings beat that they view as supporting the recent share price strength, while also questioning how much further the stock can advance beyond its recent trading range. Analyst Commentary Bullish Takeaways Bullish analysts view the Q3 result as a clean beat, which they see as supporting the recent share price move and giving the higher US$75 target some fundamental backing.Actualización de narrativa • Dec 19
HSIC: Q3 Beat And Buybacks Will Support Range-Bound Earnings Momentum
Analysts have modestly raised their price target on Henry Schein to approximately $75, reflecting a slightly higher fair value and future price-to-earnings multiple following a clean Q3 beat, even as they remain cautious about the stock meaningfully breaking out of its recent trading range. Analyst Commentary Street research following the Q3 report reflects a mix of cautious optimism and ongoing skepticism about Henry Schein's near term upside potential.Seeking Alpha • Dec 05
Henry Schein Can Make Your Portfolio Smile
Summary Henry Schein stands out as the largest global provider of healthcare products and services for office-based dental and medical practitioners, with a strong market share. HSIC continues to deliver solid growth, reporting Q3 revenue up 5.2% year-over-year and improved profitability across all segments, driven by internal growth and targeted programs. Management anticipates ongoing revenue and EBITDA growth, supported by demographic trends, increased healthcare access, and technological advancements like AI in dental care. Shares are attractively valued relative to peers, justifying a soft "Buy" rating for this high-quality industry leader with promising expansion catalysts. Read the full article on Seeking AlphaActualización de narrativa • Dec 05
HSIC: Q3 Beat And Capital Returns Will Support Measured Earnings Momentum
Analysts modestly raised their price target on Henry Schein to $75 from $71, citing a clean Q3 beat that supports recent share gains while still questioning the stock's ability to break out above its historically defined trading range. Analyst Commentary Analysts highlight that the latest quarter delivered a clean beat versus expectations, reinforcing confidence in Henry Schein's ability to execute on its operating plan despite macro and industry headwinds.Actualización de narrativa • Nov 20
HSIC: Operational Improvements and Automation Are Expected to Support Earnings Momentum
Analysts have increased their price target for Henry Schein from $75 to $77, citing expectations for moderate improvements in revenue growth and future earnings. They also pointed to optimism driven by recent operating performance and strategic initiatives.Actualización de narrativa • Nov 05
HSIC: Earnings Momentum From Automation And E-Commerce Will Shape Outlook
Henry Schein’s analyst price target has increased from $73.23 to $75.15 per share, reflecting analysts’ confidence in improving margins and strategic initiatives following recent earnings results. Analyst Commentary Following the company's recent performance and updated guidance, research analysts have issued new commentary highlighting both upward momentum and remaining concerns regarding Henry Schein's outlook.Artículo de análisis • Aug 08
Henry Schein, Inc. Just Missed EPS By 24%: Here's What Analysts Think Will Happen Next
NasdaqGS:HSIC 1 Year Share Price vs Fair Value Explore Henry Schein's Fair Values from the Community and select yours...Seeking Alpha • Mar 11
Henry Schein Looks Bullish (Technical Analysis)
Summary HSIC shows bullish price action, momentum, volume, and relative strength, making it an attractive investment with a 2.6 reward-to-risk ratio. The stock is in an uptrend, trading above its 30-week EMA, and has bullish short-term and long-term momentum as indicated by the PPO. Institutional buying supports bullish volume trends, and HSIC has been outperforming the S&P 500 since December 2024. Despite recent earnings not meeting expectations, future earnings and revenue growth, along with sector strength, indicate potential for price targets of $82.63 and $92.68. Read the full article on Seeking AlphaSeeking Alpha • Mar 04
Henry Schein: An Industry Leader That Offers Some Upside From Here
Summary Henry Schein is the world's largest provider of healthcare products and services for office-based dental and medical practitioners, showing consistent growth through acquisitions. Despite a 3% dip in shares, management's 2025 guidance indicates continued growth, justifying a bullish stance on the stock. The firm reported a 5.8% revenue increase in Q4 2024, driven by organic growth and acquisitions, with significant improvements in net income and operating cash flow. Henry Schein's market leadership and strategic acquisitions across various healthcare segments make it a solid investment, warranting a soft 'buy' rating. Read the full article on Seeking AlphaSeeking Alpha • Dec 10
Henry Schein: The Kind Of Business I Like But No Margin Of Safety Now
Summary Although the U.S. stock market is currently 6.9% overvalued, according to Morningstar's analysts as of December 6, 2024, there could be opportunities in undervalued sectors like healthcare. Henry Schein is a candidate surfaced by a screen in this sector. It has many characteristics that I like in companies: easy-to-understand business, and profitable, among many others. There are some short-term headwinds that investors must be aware of but not overly concerned about. No investment is so good that it is worth buying at any price, and that applies to Henry Schein, which is currently overvalued. Read the full article on Seeking AlphaSeeking Alpha • Nov 20
Henry Schein: Another Day, Another Purchase
Summary Henry Schein announced the acquisition of Acentus, a small medical product supplier, to expand its homecare medical products platform despite recent underperformance in cash flow metrics. The CGM market, where Acentus operates, is expected to grow significantly, making the acquisition strategically sound, though financial benefits remain uncertain without disclosed terms. Despite revenue growth from acquisitions, Henry Schein's profitability metrics have declined, raising concerns about its ability to meet its revised 2024 revenue and profit targets. While Henry Schein shows potential for cost savings and slight undervaluation, persistent profitability issues and investor skepticism warrant only a cautious 'buy' rating, subject to future performance. Read the full article on Seeking Alpha
Nueva narrativa • Aug 25
Critical Acquisitions And High-Growth Product Expansion Set To Transform Dental Giant
Expansion into high-growth products and strategic acquisitions aimed at increasing gross margins through improved integration and efficiency.Seeking Alpha • May 23
Henry Schein: Acquisition Strategy Isn't Pulling Its Economic Weight
Summary Henry Schein, Inc. came in with flat revenue growth in Q1 FY'24, with most expansion coming from acquisitions. The company's capital allocation strategy, focused on acquisitions, is not creating economic value for shareholders in my view. Based on my analysis, the company's performance does not justify a higher valuation. Read the full article on Seeking AlphaRentabilidad de los accionistas
| HSIC | US Healthcare | Mercado US | |
|---|---|---|---|
| 7D | 2.0% | -0.4% | 1.0% |
| 1Y | 3.6% | 16.3% | 28.7% |
Rentabilidad vs. Industria: Los resultados de HSIC fueron inferiores a los de la industria US Healthcare, que obtuvo un rendimiento del 16.3% el año pasado.
Rentabilidad vs. Mercado: HSIC obtuvo unos resultados inferiores a los del mercado US, que fueron del 28.7% el año pasado.
Volatilidad de los precios
| HSIC volatility | |
|---|---|
| HSIC Average Weekly Movement | 3.6% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: HSIC no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HSIC (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1932 | 25,000 | Fred Lowery | www.henryschein.com |
Henry Schein, Inc. ofrece productos y servicios sanitarios a odontólogos y médicos de todo el mundo. Opera a través de los segmentos de Distribución Global y Servicios de Valor Añadido, Productos Especiales Globales y Tecnología Global. El segmento de Distribución Global y Servicios de Valor Añadido distribuye productos para el control de infecciones, piezas de mano, preventivos, materiales de impresión, composites, anestésicos, dientes, yeso, acrílicos, articuladores, abrasivos, productos EPI, productos farmacéuticos de marca y genéricos, vacunas, productos quirúrgicos, pruebas diagnósticas, sillones dentales, unidades de suministro y lámparas, laboratorios dentales digitales, suministros y equipos de rayos X y equipos de restauración digitales y de alta tecnología, así como servicios de reparación de equipos, servicios financieros sin recurso, servicios de formación continua para profesionales, consultoría y otros servicios.
Resumen de fundamentos de Henry Schein, Inc.
| Estadísticas fundamentales de HSIC | |
|---|---|
| Capitalización bursátil | US$8.37b |
| Beneficios(TTM) | US$395.00m |
| Ingresos (TTM) | US$13.38b |
21.4x
Ratio precio-beneficio (PE)0.6x
Ratio precio-ventas (PS)¿Está HSIC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HSIC | |
|---|---|
| Ingresos | US$13.38b |
| Coste de los ingresos | US$9.21b |
| Beneficio bruto | US$4.18b |
| Otros gastos | US$3.78b |
| Beneficios | US$395.00m |
Últimos beneficios comunicados
Mar 28, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 3.47 |
| Margen bruto | 31.19% |
| Margen de beneficio neto | 2.95% |
| Ratio deuda/patrimonio | 70.6% |
¿Cómo se ha desempeñado HSIC a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 16:28 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/28 |
| Ingresos anuales | 2025/12/27 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Henry Schein, Inc. está cubierta por 33 analistas. 15 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Jeffrey Johnson | Baird |
| Lawrence Marsh | Barclays |
| Glen Santangelo | Barclays |